Metabolic disorder

Inversago Pharma Announces New Data to be Presented at the 2023 American Thoracic Society International Conference

Retrieved on: 
Monday, May 22, 2023
Research, Diabetes, Cardiology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Faculty, Asthma, Obesity, University, University of Vermont, ATS, Weight loss, Quality of life, Metabolic disorder, Robert Larner College of Medicine, Inflammation, Doctor of Philosophy, Model, American Thoracic Society, International Conference on Nuclear Disarmament, Oslo, 2008, Syndrome, CB1, Adipose tissue, Conference, Pharmaceutical industry

Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C.

Key Points: 
  • Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C.
  • INV-202, Inversago’s lead drug candidate, is a potential first-in-class, peripheral CB1r blocker, being developed to treat metabolic disorder complications.
  • “INV-202 is being developed for the treatment of metabolic disorder complications, and this preclinical data demonstrates its potential to also address the large unmet need in asthma complicated by obesity,” added Glenn Crater MD, Chief Medical Officer of Inversago.
  • Abstract Title: Cannabinoid Receptor 1 Inverse Agonist, INV-202, Induces Weight Loss and Reduces Airway Hyperreactivity in a Mouse Model of Obese Asthma

Novel Genetic Screening Tool Offers Hope for Babies Born With Life-Threatening Metabolic Disorder

Retrieved on: 
Thursday, May 4, 2023
Seizure, Journal of Inherited Metabolic Disease, UCDC, Pediatrics, Ornithine transcarbamylase deficiency, American Journal of Human Genetics, Hope, Metabolic disorder, Brain, Child, George Washington University, Bangladesh Technical Education Board, Associate, DSM-IV codes, Science, Human genetics, Children's National Hospital, Disorder, Genetics, American Journal, Data, Metabolism, Patient, Physician, Ammonia, Blood, Risk, OTC, Diagnosis, Gene, Disease, Dietary supplement

SEATTLE, May 4, 2023 /PRNewswire-PRWeb/ -- Every expectant parent hopes to welcome a healthy baby into the world. Unfortunately, infants with some genetic diseases appear healthy at birth, but then rapidly deteriorate—they become lethargic, stop eating, develop seizures, and may progress to coma—symptoms common to a variety of metabolic disorders. For the physicians charged with their care, it is a race against time to determine which disorder is causing their fragile patient to decline.

Key Points: 
  • For the physicians charged with their care, it is a race against time to determine which disorder is causing their fragile patient to decline.
  • A study published today in the American Journal of Human Genetics describes the tools that the Dudley Lab developed to assess the changes in a genetic sequence (variant) associated with ornithine transcarbamylase deficiency ( OTC deficiency ), a rare, inherited metabolic disorder.
  • "We hope that our data will also accelerate the development of new treatments and cures for OTC deficiency."
  • The technology built by the Dudley Lab at PNRI offers hope for a brighter future for infants with life-threatening metabolic diseases.

Longeveron Appoints Wa’el Hashad as Chief Executive Officer

Retrieved on: 
Tuesday, February 28, 2023
David Berry (inventor), Marketing, Boehringer Ingelheim, Eli Lilly and Company, Biotechnology, Therapy, MSC, Boehringer, University, Strategic Advisory Board for Intellectual Property Policy, Amgen, Drug development, Interim, Plasma protein binding, Eli Lilly, FDA, Metabolic disorder, Neuroscience, Medication, Growth, Fortune 500, American University in Cairo, Hypoplastic left heart syndrome, Washington State University College of Pharmacy and Pharmaceutical Sciences, Food and Drug Administration, Central Waqf Council, International business, Food, Otsuka Pharmaceutical, Pharmaceutical industry, Management, Pharmacy, Shimaa Hashad

MIAMI, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing regenerative medicines for rare pediatric disease, aging-related conditions, and unmet medical needs, today announced the appointment of seasoned global pharmaceutical leader Wa’el Hashad as Chief Executive Officer. Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023. Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer.

Key Points: 
  • Mr. Hashad will assume the role of Chief Executive Officer effective March 1, 2023.
  • Following Mr. Hashad joining Longeveron, current Interim Chief Executive Officer Chris Min, M.D., Ph.D., will continue in his role as Chief Medical Officer.
  • “The Board and I are delighted to welcome Mr. Hashad to Longeveron to lead the company through its next stage of growth.
  • Prior to Avanir, Mr. Hashad was Executive Vice President and Chief Commercial Officer at Seres Therapeutics, where he established the company’s launch and marketing strategy for microbiome-based therapies.

EQS-News: Rentschler Biopharma awarded Chiesi Supplier Award

Retrieved on: 
Sunday, January 22, 2023
Benefit corporation, Hearing loss, B Corporation (certification), Partnership, Supplier, Central nervous system, Record, Research, Pfizer, Disease, Thought, Muscle weakness, CDMO, Alpha-mannosidosis, Quality Technology Services, Business development, Patient, Metabolic disorder, Degenerative disease, Sugar, Service, Senior, Environment, Pharmaceutical industry, Fine chemical, Merck, EU, Chiesi Farmaceutici

Laupheim, Germany, December 19, 2022 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that its long-standing client, Chiesi Group, recently presented Rentschler Biopharma with the We Excel in Innovation and Collaboration Award.

Key Points: 
  • Laupheim, Germany, December 19, 2022 - Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that its long-standing client, Chiesi Group, recently presented Rentschler Biopharma with the We Excel in Innovation and Collaboration Award.
  • Rentschler Biopharma won the We Excel in Innovation and Collaboration Award, given to companies with outstanding records in these areas based on an internal assessment survey.
  • Rino Visentin, Manager External Manufacturing at Chiesi Group, who presented the award, commented: “It is a great pleasure for Chiesi to reward the excellence of Rentschler Biopharma as a true example of a partnership that has been going on for more than seven years.
  • Rentschler Biopharma has been working with Chiesi (previously Zymenex, which was acquired by Chiesi) to manufacture the biological active substance for Lamzede®, a recombinant enzyme since 2009.

GeneType published in PLOS ONE – development of polygenic risk scores for cardiovascular diseases and type 2 diabetes

Retrieved on: 
Tuesday, December 6, 2022
Atrial fibrillation, PRS, Associate, Physician, Health, ASX, Metabolism, Cardiovascular disease, Hypertension, Degenerative disease, Science, Death, Stroke, Applied Genetic Technologies Corporation, Genetic, Genetypes, GTG, Coronary artery disease, Epidemiology, Diabetes, Metabolic disorder, Type 2 diabetes, Disease, Professor, Biobank, Risk assessment, Risk, University, UK Biobank, Medical device, Pharmaceutical industry, Toy, Medical imaging, Biostatistics

The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.

Key Points: 
  • The study used advanced statistical techniques to develop polygenic risk scores for coronary artery disease, hypertension, atrial fibrillation, stroke and type 2 diabetes.
  • The cutting-edge study design meant that the polygenic risk scores developed by GTG use just the genetic changes essential to predict risk without sacrificing predictive performance compared with polygenic risk scores that use up to 820 times the number of genetic changes.
  • GTG quantified the true effects of the polygenic risk scores in predicting disease by accounting for age and sex in the study design.
  • The company’s Polygenic Risk Scores (PRS) platform is a proprietary risk stratification platform developed over the past decade integrating clinical and genetic risk delivering actionable outcomes from physicians and individuals.

Baszucki Brain Research Fund Announces Metabolic Psychiatry Fellow Dr. Iain Campbell

Retrieved on: 
Wednesday, December 7, 2022
Fund, United Kingdom, Roblox, University, Global health, Metabolic disorder, Bipolar disorder, Research, Diabetes, University of Edinburgh, Mental health, Microdeletion syndrome, Brain, Doctor of Philosophy, SAN, Risk, Medical device, Pharmaceutical industry

SAN MATEO, Calif., Dec. 7, 2022 /PRNewswire/ -- Today, the Baszucki Brain Research Fund is proud to announce Dr. Iain Campbell as its first Metabolic Psychiatry Research Fellow. During the four-year fellowship and through an investment of $380,000, Dr. Campbell will extend the University's current research program on ketogenic metabolic therapy for bipolar disorder to include mechanistic controlled clinical trials. His work will also focus on raising awareness through podcasting and online content, and on empowering advocates within the bipolar disorder community to encourage participation in research.

Key Points: 
  • Dr. Iain Campbell will lead pioneering studies of Ketogenic Metabolic Therapy for Bipolar Disorder at the University of Edinburgh, one of the United Kingdom's leading research centers
    SAN MATEO, Calif., Dec. 7, 2022 /PRNewswire/ -- Today, the Baszucki Brain Research Fund is proud to announce Dr. Iain Campbell as its first Metabolic Psychiatry Research Fellow.
  • The Baszucki Brain Research Fund intends to sponsor additional fellowships in Metabolic Psychiatry in the coming years.
  • The Baszucki Brain Research Fund, part of Baszucki Group , was launched in 2020 by Roblox founder and CEO David Baszucki and best-selling author Jan Ellison Baszucki.
  • It aims to fight stigma by catalyzing research and advancements in clinical care, with a focus on metabolic neuroscience, metabolic psychiatry and ketogenic interventions for mental health.

Medical Foods Global Market to Reach $24.11 Billion by 2026 at a CAGR of 5.61% - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022
Fitness & Nutrition, Health, Online, Health, PKU, Ageing, Growth, Metabolic disorder, ADHD, Phenylketonuria, WHO, Diabetic neuropathy, Malnutrition, Patient, Alzheimer's disease, Intake, Disease, Risk, Death, Agriculture, Pharmaceutical industry

Medical food pills are specially formulated to meet nutritional requirements of patients with various medical conditions such as digression, ADHD, and others.

Key Points: 
  • Medical food pills are specially formulated to meet nutritional requirements of patients with various medical conditions such as digression, ADHD, and others.
  • The regions covered in the medical foods market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increase in the geriatric population is significantly contributing to the growth of the medical foods market.
  • Therefore, the increase in the geriatric population is expected to propel the growth of the medical foods market.

iECURE Raises $65 Million to Advance In Vivo Gene Editing Programs for the Treatment of Rare Pediatric Liver Diseases

Retrieved on: 
Wednesday, November 30, 2022
Health, Genetics, Clinical Trials, Research, Science, Biotechnology, GTP, Growth, University, Gene editing, Series, Phenylketonuria, OTC, Novo Nordisk Foundation, Metabolic disorder, Novo Holdings A/S, Precision, Blood, Nerve, Doctor of Philosophy, IND, Novo Nordisk, Risk, Mutation, James Wilson, Life, University of Pennsylvania, Patient, Primate, Coma, Liver, PKU, Genome, FDA, Disease, CAR, Ornithine transcarbamylase deficiency, PCSK9, Infection, Death, Research, Gene expression, Ammonia, AAV, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Management, Antibiotics, Vaccine

In addition, the Series A-1 financing is expected to fuel further progress on iECUREs portfolio of gene editing products for the treatment of patients with rare liver diseases, including citrullinemia type 1 (CTLN1) and phenylketonuria (PKU).

Key Points: 
  • In addition, the Series A-1 financing is expected to fuel further progress on iECUREs portfolio of gene editing products for the treatment of patients with rare liver diseases, including citrullinemia type 1 (CTLN1) and phenylketonuria (PKU).
  • The FDA has granted both Orphan Drug Designation and Rare Pediatric Designation to GTP-506 for the treatment of OTC deficiency.
  • iECURE is a gene editing company focused on developing therapies that utilize mutation-agnostic in vivo gene insertion, or knock-in, editing for the treatment of liver disorders with significant unmet need.
  • 1 iECURE has licensed the ARCUS nuclease from Precision BioSciences for four gene insertion programs including OTC, CTLN1 and PKU.

Aeglea BioTherapeutics Appoints Jeffrey M. Goldberg as Chief Executive Officer

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, Doctor of Philosophy, JD, European Medicines Agency, Intellectual disability, MAA, Piper Sandler Companies, Frank Lenti, MS, Osteoporosis, Engineering, Metabolic disorder, Conference, Compte rendu, Multimedia, Therapy, Physician, Enzyme, MBA, Patient, Massachusetts Institute of Technology, Genzyme, Disease, CBS, Cornell University, Marfanoid, Security (finance), Proteostasis, Death, Risk, Arginine, Chemical engineering, Pharmaceutical industry, Management, Homocystinuria

Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.

Key Points: 
  • Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics.
  • I look forward to working closely with Jeff and welcome him to the Aeglea team."
  • Mr. Goldberg served as president and chief executive officer at Immunitas from 2019-2021.
  • Jim Kastenmayer, JD, PhD, will step down as interim chief executive officer and retain his position as Aeglea's general counsel.

Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease

Retrieved on: 
Tuesday, November 29, 2022
Health, Diabetes, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, DN, Doctor of Philosophy, European Renal Association – European Dialysis and Transplant Association, T2D, Metabolic disorder, Conditional sentence, CB1, Kidney disease, Hypertriglyceridemia, DKD, Patient, Fatty liver disease, Diabetic nephropathy, HTG, T1D, NASH, Pancreas, Chronic kidney disease, Disease, Standard of care, Diabetes, Muscle, IPF, Obesity, Liver, Idiopathic pulmonary fibrosis, Pharmaceutical industry, MD

Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).

Key Points: 
  • Inversago Pharma Inc. (Inversago), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
  • Participants will receive once-daily oral doses of 10 or 25mg of INV-202 or placebo during the 16-week study.
  • This study builds on positive Phase 1b data that will be presented at a future scientific conference.
  • INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease.